Teva Pharmaceuticals and Alvotech expand biosimilars partnership
Teva Pharmaceuticals Industries Ltd. (TEVA.TV) and Alvotech (ALVO) announced Monday that they are expanding their collaboration in the U.S. biosimilars market. Under the agreement, two new biosimilar candidates and line extensions of two current biosimilar candidates developed and manufactured by Alvotech will be commercialized in the U.S. by Teva. The agreement includes milestone payments based on product approvals and sales, and the two companies will share profits from the commercialization of the biosimilars. Teva will also acquire subordinated convertible bonds issued by Alvotech, the companies said in a release. The companies were already collaborating on biosimilars for blockbuster drugs such as AbbVie Inc.'s (ABBV) Humira and Johnson & Johnson's (JNJ) Stelara. Alvotech shares gained more than 5% premarket on Monday, while Teva shares are up 0.2%.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-24-23 0852ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
Going Into Earnings, Is Eli Lilly Stock a Buy, a Sell, or Fairly Valued?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Paramount Earnings: CEO Has Gone, For-Sale Sign Is Up; Good Results Would’ve Been Nice to Learn
-
After Earnings, Is Tesla Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is GE Aerospace Stock a Buy, a Sell, or Fairly Valued?
-
3 Good Stocks to Buy with Your Tax Refund in 2024 (Or with Any Extra Money)
-
SoFi Earnings: Revenue Growth Slows on Lower Loan Growth and Higher Credit Costs
-
Tesla: Full Self-Driving Approval In China Supports Our View for Deliveries Growth In 2024
-
Philips Earnings: Firm Reaches $1.1 Billion Settlement Agreement
-
AbbVie Earnings: Next-Generation Immunology Drugs Help Offset Humira Biosimilar Pressure